CLAIMS

What is claimed is:

1. A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of:

administering as a transdermal patch, a composition comprising oxybutynin to said subject to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1, wherein the transdermal patch includes an effective amount of a permeation enhancer selected from the group consisting essentially of: fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol di- and monoesters, short chain alcohols, and mixtures thereof.

2. The method of claim 1, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 1:1 to about 5:1.

3. The method of claim 2, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 0.8:1 to about 1.5:1.

4. The method of claim 1, wherein the metabolite of oxybutynin is N-desethyloxybutynin.

5. The method of claim 4, wherein the N-desethyloxybutynin is (R)-N-desethyloxybutynin, (S)-N-desethyloxybutynin or a combination thereof.

6. The method of claim 1, wherein the oxybutynin is a mixture of R-oxybutynin and S-oxybutynin.

7. The method of claim 6, wherein the oxybutynin is R-oxybutynin.

8. The method of claim 1, wherein the enhancer is a fatty acid.

9. The method of claim 1, wherein the enhancer is a fatty acid ester.

10. The method of claim 1, wherein the enhancer is a fatty alcohol.

11. The method of claim 1, wherein the enhancer is a short chain alcohol.

12. The method of 1, wherein the enhancer is a glycerol monoester.

13. An article of manufacture for transdermal application comprising:

a transdermal patch including a composition of oxybutynin and an effective amount of a permeation enhancer selected from the group consisting essentially of: fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol di- and monoesters, short chain alcohols, and mixtures thereof, for administration to a human subject, wherein the patch provides, upon administration to said subject, a plasma AUC ratio of oxybutynin to an oxybutynin metabolite from about 0.5:1 to about 5:1, and wherein said patch minimizes an anticholinergic or antimuscarinic adverse drug experience associated with the administration of oxybutynin.

14. The article of manufacture of claim 13, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 1:1 to about 5:1.

15. The article of manufacture of claim 14, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 0.8:1 to about 1.5:1.

16. The article of manufacture of claims 13, wherein the metabolite of oxybutynin is N-desethyloxybutynin.

17. The article of manufacture of claim 16, wherein the N-desethyloxybutynin is (R)-N-desethyloxybutynin, (S)-N-desethyloxybutynin or a combination thereof.

18. The article of manufacture of claim 13, wherein the oxybutynin is a mixture of R-oxybutynin and S-oxybutynin.

19. The article of manufacture of claim 18, wherein the oxybutynin is R-oxybutynin.

20. The article of manufacture of claim 13, wherein the enhancer is a fatty acid.

21. The article of manufacture of claim 13, wherein the enhancer is a fatty acid ester.

22. The article of manufacture of claim 13, wherein the enhancer is a fatty alcohol.

22. The article of manufacture of claim 13, wherein the enhancer is a short chain alcohol.

24. The article of manufacture of claim 13, wherein the enhancer is a glycerol monoester.